Medical Device | May 20, 2026
Boston Scientific invests $1.5 billion in MiRus for TAVR expansion
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
The development comes as stroke remains one of the world’s biggest health threats
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Baxfendy works in a fundamentally different way from current therapies
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
